Who Should Own Evidence-Recency Decisions in Reinsurance?

The Decision Nobody Owns Until a Renewal Forces the Question

Underwriting evidence that ages too quickly is not primarily a data problem. It is a decision-rights problem, because nobody has clearly been assigned to decide when evidence is too old to trust.

That gap sits at the boundary between underwriting, actuarial, and medical judgment, which is exactly the kind of boundary that tends to default to informal practice when no single function is accountable for it. The risk-diagnosis case for why this matters is laid out in why underwriting evidence ages too quickly for reinsurers to trust.

This post is about who should actually be making the call, and how.

Who Should Own Evidence-Recency Policy?

The Chief Underwriting Officer should own the standard itself, with mandatory input from the Chief Actuary and Chief Medical Officer.

Underwriting is where evidence gets collected and evaluated, which makes the CUO the natural owner of the operational standard. But the standard cannot be set in isolation.

The Chief Actuary needs to weigh in because evidence-recency assumptions feed directly into pricing and reserving. The Chief Medical Officer needs to weigh in because deciding how fast a given evidence type decays is a clinical judgment, not just an operational one.

A standard set by only one of these three functions will systematically miss something the other two would have caught.

Why Does This Ownership Question Get Skipped?

It gets skipped because none of the three functions sees the full cost of the gap on its own.

Underwriting sees the operational friction of requiring fresher evidence, which looks like a cost with no obvious owner-side benefit. Actuarial sees the pricing impact only after it shows up in claims experience, years after the underwriting decision was made.

Medical sees the clinical reality but rarely gets asked to weigh in on operational thresholds. Each function is missing a different piece of the picture, which is exactly why joint ownership, not single-function ownership, is the right structure.

What Is the Core Decision Executives Actually Need to Make?

The core decision is when to require refreshed evidence versus when to accept evidence as-is, set explicitly rather than left to underwriter discretion.

This cannot be a single blanket rule. Different evidence types decay at different rates, so a workable standard has to be evidence-type-specific, not a single "evidence must be under X months old" policy applied uniformly.

Treaty duration matters too. A one-year renewable term treaty can tolerate a looser recency standard than a thirty-year life treaty, because the shorter treaty gets corrected at the next renewal regardless.

Should Accelerated Underwriting Books Get a Different Standard?

Yes, because accelerated books lean more heavily on alternative data sources that carry their own recency gaps.

Prescription histories and EHR pulls are often fresher than a scheduled exam, but not always, and not for every data element. A standard built around traditional exam cadence does not automatically translate to a book underwritten primarily on alternative data.

Executives need a separate, explicit calibration for accelerated books, one that accounts for which alternative data sources are actually being used and how current each one tends to be in practice. Treating accelerated and traditional books under the same recency assumption is a common and avoidable gap.

How Should Reinsurers Push Cedants Toward Better Practice?

By making evidence-recency standards an explicit, scored component of cedant underwriting guideline reviews.

Most cedants will not have a documented answer to "how long is evidence valid before it must be refreshed" unless they are specifically asked. Making that question a standard, scored part of due diligence forces the answer into the open before it becomes a claims dispute.

This also gives a reinsurer comparable data across its cedant portfolio. Once evidence-recency practice is scored consistently, a reinsurer can see which cedants carry more exposure on this dimension and price or structure treaties accordingly.

What Does This Cost If It Stays Unowned?

It costs a reinsurer the ability to see and price for inconsistent cedant practice until it shows up in diverging claims experience.

An unowned decision does not mean no decision gets made. It means the decision gets made informally, inconsistently, by whichever underwriter happens to be handling a given file, with no aggregation across cedants and no feedback loop back into pricing.

That is the most expensive version of this problem, because it is invisible right up until the moment it is not. By the time it shows up in actual-to-expected data, several years of business have already been written under the same unexamined practice.

Reinsurers that have already built evidence-recency scoring into cedant reviews are the ones who can act on early signal instead of discovering the gap after it has compounded, a distinction covered from the operational-fix side in how better workflow design reduces underwriting evidence that ages too quickly.

How Often Should This Policy Be Revisited?

At minimum annually, and immediately whenever a new class of evidence-sensitive treatment or condition emerges.

An annual review keeps the standard aligned with how underwriting and clinical practice are actually evolving. But annual alone is not enough when something changes fast, the way GLP-1 medications changed how quickly BMI and weight readings can go stale.

Executives should build a trigger into governance that forces an off-cycle review whenever a development like that surfaces, rather than waiting for the next scheduled annual check. Tools like an Underwriting Assumption Validator AI Agent can help flag exactly this kind of emerging gap between what a standard assumes and what current clinical practice actually looks like.

What Does a Mature Governance Model Look Like End to End?

It looks like a written, evidence-type-specific standard with joint ownership and a defined review cadence, not a policy that only gets attention after something has gone wrong.

That means a documented threshold for each major evidence type, explicit sign-off from underwriting, actuarial, and medical leadership, and a review cycle that is scheduled rather than reactive. It also means the standard is visible to cedants as part of treaty negotiation, not something a reinsurer quietly applies on its own side without saying so.

What Happens When the Three Functions Disagree?

Disagreement between underwriting, actuarial, and medical leadership on an evidence-recency threshold should be resolved through a defined escalation path, not left unresolved by default.

In practice, underwriting will often favor looser standards that preserve issuance speed, while actuarial will favor tighter standards that protect pricing accuracy, and medical will weigh in based on clinical judgment about how fast a given condition can actually change. All three positions are legitimate, which is exactly why an undefined resolution process tends to produce whichever position was loudest in the room, rather than the position best supported by evidence.

A workable escalation path names a final decision-maker, typically the CUO for operational thresholds and the Chief Actuary for anything with material pricing implications, and requires that disagreements be documented along with the reasoning on each side. That documentation matters later, because it gives the organization a record to revisit when a threshold turns out to have been set too loosely, rather than relying on institutional memory of an informal debate.

How Should This Show Up in Executive Accountability Structures?

Evidence-recency standard-setting should be an explicit, named responsibility in the relevant executive's performance objectives, not an implicit expectation nobody has formally assigned.

Responsibilities that exist only informally tend to receive informal attention. Making evidence-recency governance a named objective for the CUO, with defined deliverables like an annual standard review and a cedant scoring process, changes it from something that might get attention to something that is expected to get attention on a schedule.

This is a small governance change with an outsized effect, because it is the difference between a standard that exists because someone happened to prioritize it this year, and a standard that exists because it is a defined part of a role, regardless of who is filling that role or what else is competing for their attention.

How Should Smaller Reinsurers Approach This Without a Large Actuarial Bench?

Smaller reinsurers should assign this responsibility explicitly even without a large team, since the decision-rights gap this post describes is a matter of clear ownership, not headcount.

A large actuarial and medical bench makes it easier to run detailed correlation and staleness analysis, but a small organization can still name a single accountable executive, document a basic evidence-type-specific standard, and review it annually. The core fix described throughout this post, closing an ownership gap, does not require significant resources to begin.

What smaller organizations should avoid is treating limited resources as a reason to skip ownership entirely, since an undefined standard costs the same in exposure whether the organization is large or small, while the fix costs considerably less to implement at a smaller scale. Starting simple and formal beats staying informal and comprehensive, particularly for an organization without the bench strength to catch an informally managed gap before it compounds.

A smaller reinsurer can also lean on retrocession partners or outside actuarial consultants for the periodic deeper analysis a larger peer would run internally, as long as the ownership and the annual review commitment stay with a named executive inside the organization itself.

Sources

• RGA: RGA GLP-1 Study: Weighing the Evidence
• RGA: Accelerated Underwriting: Maximizing its Future